Shares of Galectin Therapeutics, Inc. (GALT) are up almost 14% to $6.00 in pre-market trading Monday after the company presented data from its Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis at The Liver Meeting in Boston, Massachusetts. Galecting said that overall, data from the multi-center, partially blinded Phase 1 trial showed that administration of 2, 4 and 8 mg/kg lean body weight of GR-MD-02 intravenously for four doses over 6 weeks was safe and well tolerated. Thus, the primary endpoint of the study has been met.
Separately, Galectin today reported its financial results for the third quarter. The company handed in earnings of ($0.17) versus ($0.27) single estimate.
Galectin Therapeutics is currently valued at $116.39M. In the past 52 weeks, shares of Norcross, Georgia-based company have traded between a low of $4.28 and a high of $19.11 with the 50-day MA and 200-day MA located at $5.05 and $8.89 levels, respectively.
GALT currently prints a one year loss of about 41%, and a year-to-date loss of around 34.65%.
Achillion Pharmaceuticals (ACHN) shares rallied more than 7% pre-market after the company reported 100% SVR12 in a phase 2 combination study with ACH-3102 at the Liver Meeting 2014 (AASLD).
On valuation-measures, shares of Achillion Pharmaceuticals have a P/E to growth ratio of (2.90) and a t-12 negative return on equity of 42.79%. EPS is at ($0.62). The company has a market cap of $988 million and a median Wall Street price target of $12.00 with a high target of $22.00.
ACHN has a Relative Strength Index (RSI) of 39.05 and MACD indicator of (1.07).
The name currently prints a one year return of about 314.34%, and a year-to-date return of around 204.52%.
Achillion Pharmaceuticals, Inc., develops and commercializes anti-infective drug therapies in the U. S. and internationally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Shares of San Mateo, California-based GoPro, Inc. (GPRO) advanced to $79.06 at the close Friday in New York and have plunged nearly 7% in pre-market trading Monday, after the company filed for a $800M Class A common stock offering by company and selling stockholders.
From a valuation perspective, GoPro, Inc. shares are currently priced at 212.53x this year’s forecasted earnings compared to the industry’s 23.51x earnings multiple. Ticker has a PEG and forward P/E ratio of 2.07 and 64.28, respectively. Price/sales for the same period is 8.83 while EPS is $0.37. Currently there are 3 analysts that rate GPRO a ‘Buy’, while 10 rate it a ‘Hold’. 1 analyst rates it a ‘Sell’. GPRO has a median Wall Street price target of $90.00 with a high target of $105.00.
Shares are up 152.27% year-to-date.
Shares of Alibaba Group (BABA) are up 2.70% to $117.26 in pre-market trading Monday, marking the Chinese e-commerce giant’s largest intraday gain since its U.S. market debut. Not seeing any news to account for the name’s new all-time high, except post-earnings momentum.
Alibaba shares are currently priced at 52.67x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 28.34x earnings multiple. The company’s next year EPS growth estimate is 36%, compared to the industry growth rate of 23.90%. BABA has a t-12 price/sales ratio of 30.02. EPS for the same period registers at $2.17.
Alibaba’s shares have advanced 29.02% in the last 4 weeks. Over the past 5 trading sessions the stock has gained 16.19%. Shares of Alibaba are up 22.02% year-to-date.
The e-commerce giant is currently valued at $282.39B with a median Wall Street price target of $120.00 and a high target of $135.00.
BlackBerry Limited (BBRY) is higher by approximately 2% this morning after Chief Executive Officer John Chen said “he’s interested in partnerships to expand in China, the world’s largest smartphone market, after meeting the heads of Xiaomi Corp. and Lenovo Group Ltd.”
BlackBerry shares recently gained $0.36 to $10.89. In the past 12 months, shares of Waterloo, Canada-based company have traded between a low of $5.44 and a high of $11.65. Shares are up 61.75% year-over-year, and 41.53% year-to-date.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!